Imagen de Portada

Development and Validation of the Pharmacological Statin‐Associated Muscle Symptoms Risk Stratification Score Using Electronic Health Record Data

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Boguang Sun, Pui Ying Yew, Chih‐Lin Chi, Meijia Song, Matt Loth, Yue Liang, Rui Zhang, Robert J. Straka
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Uncovering Coenzyme Q10 ‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program
por: Da Hoon Lee, et al.
Publicado: (2026)

Risk of Opioid Overdose Associated with Concomitant Use of Methadone and Statins
por: Cheng Chen, et al.
Publicado: (2024)

Editorial: Tumour Burden Score and Extrahepatic Progression After TACE —Refining Risk Stratification Beyond the Liver
por: Chien‐Wei Su
Publicado: (2026)

Establishing a Validation Framework of Treatment Discontinuation in Claims Data Using Natural Language Processing and Electronic Health Records
por: Chun‐Ting Yang, et al.
Publicado: (2025)

Letter: Enhancing HCC Surveillance– GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety
por: Ibrahima Gueye
Publicado: (2025)

Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance
por: Jian‐Jun Li, et al.
Publicado: (2024)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
por: Gamal Shiha, et al.
Publicado: (2025)

Minimizing Racial Algorithmic Bias when Predicting Electronic Health Record Data Completeness
por: Priyanka Anand, et al.
Publicado: (2025)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
por: R. Sinha, et al.
Publicado: (2025)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
por: Deliang Huang, et al.
Publicado: (2026)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
por: Daniel Q. Huang, et al.
Publicado: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
por: Takefumi Kimura
Publicado: (2025)

Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature
por: Patrick J. Arena, et al.
Publicado: (2025)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
por: Emily Stephenson, et al.
Publicado: (2026)

MELD 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome‐Acute Kidney Injury: A Multicentre Study
por: Jing Ma, et al.
Publicado: (2025)

Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof‐of‐Principle Analysis
por: Sushama Kattinakere Sreedhara, et al.
Publicado: (2026)

Discovering Severe Adverse Reactions From Pharmacokinetic Drug–Drug Interactions Through Literature Analysis and Electronic Health Record Verification
por: Eugene Jeong, et al.
Publicado: (2024)

SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity Study
por: Tanushree Haldar, et al.
Publicado: (2025)

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data
por: Eissa A. Jafari, et al.
Publicado: (2025)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
por: Abdulrahman Ismaiel
Publicado: (2026)

Modeling Supports Combinatorial Effects Between Pharmacological and Non‐Pharmacological Interventions to Prevent Opioid‐Induced Cardiac Arrest
por: Bradlee Thrasher, et al.
Publicado: (2026)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
por: Yuanyan Sun, et al.
Publicado: (2026)

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation
por: Hyun Woong Park, et al.
Publicado: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
por: Bernardo de Faria Moraes, et al.
Publicado: (2026)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
por: Bernardo de Faria Moraes, et al.
Publicado: (2026)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
por: Yixuan Zhu, et al.
Publicado: (2025)

The Future of Clinical Translational Pharmacology
por: Matthew L. Rizk, et al.
Publicado: (2026)

History and Evolution of Innovations in Clinical Pharmacology
por: Lawrence J. Lesko, et al.
Publicado: (2025)

American Society for Clinical Pharmacology and Therapeutics
Publicado: (2026)

Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care
por: Vivek C. Goodoory, et al.
Publicado: (2026)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
por: Huy X. Ngo, et al.
Publicado: (2024)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
por: Matheus Souza, et al.
Publicado: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
por: Zhejin Shi, et al.
Publicado: (2026)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
por: Yu‐Sheng Lin, et al.
Publicado: (2026)

Progress in Clinical Pharmacology in China: An Ongoing Evolution
por: Liang Zhao, et al.
Publicado: (2025)

The Role for Clinical Translational Pharmacology in Advancing Pharmacoequity
por: Sonya Tang Girdwood, et al.
Publicado: (2025)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT ‐ ACS Emulation Using National Health Insurance Claims Data
por: Li‐Wen Huang, et al.
Publicado: (2025)

Letter: Fecal VOCs in Lynch Syndrome: Sample Stability, Specificity and Statistical Validation
por: Xidi Yang, et al.
Publicado: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
por: Yu‐Sheng Lin, et al.
Publicado: (2026)

Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2026)